ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2022
The Added Value of
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Diagnostic value of dual-tracer PET/CT with [Frontiers in medicine · 2025Pooled it
- Prospective Intraindividual Comparison of Ga-68 PSMA and F-18 FDG Dual-Tracer PET/CT Imaging in Evaluation of High-Grade Prostate Cancer.World journal of nuclear medicine · 2026Article
- Emerging frontiers and challenges of artificial intelligence in PSMA-PET imaging: pioneering a new chapter in prostate cancer care.Japanese journal of radiology · 2026Review
- Low-PSMA hormone-sensitive prostate cancer: a distinct clinical and molecular state.Molecular medicine (Cambridge, Mass.) · 2026Article
- When PSMA is not enough: the diagnostic blind spots of PSMA PET/CT and the added value of [¹⁸F]FDG in high-risk prostate cancer: dual-tracer cohort study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Dual-tracer PET/CT identifies an aggressive PSMA-negative/FDG-positive phenotype predicting early failure of radical prostatectomy in treatment-naive prostate cancer.European journal of nuclear medicine and molecular imaging · 2026Article
- Patlak-PBNT: a simple population-based Patlak model to generate [EJNMMI physics · 2026Article
- Metastatic Small Cell Neuroendocrine Carcinoma of the Prostate: A Rare and Aggressive Case Report From Bangladesh.Case reports in oncological medicine · 2026Article
- PSMA-Targeted radiopharmaceuticals: from diagnosis to risk & quality of life.European journal of nuclear medicine and molecular imaging · 2025Article
- The additive value ofEuropean journal of nuclear medicine and molecular imaging · 2025Article
- MDT perspective: innovative applications of stereotactic body radiation therapy in metastatic castration-resistant prostate cancer.Prostate cancer and prostatic diseases · 2025Review
- The effect of androgen blockade on [EJNMMI research · 2025Article
- Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [European journal of nuclear medicine and molecular imaging · 2024Article
- Efficacy and safety of rechallenge with [European journal of nuclear medicine and molecular imaging · 2024Article
- Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Observational
- Analysis of Molecular Imaging Biomarkers Derived from [Cancers · 2024Article
- [Clinical Value of Dual Tracer PET Imaging WithSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024Article
- Developments in radionanotheranostic strategies for precision diagnosis and treatment of prostate cancer.EJNMMI radiopharmacy and chemistry · 2024Review
- Combination of [European journal of nuclear medicine and molecular imaging · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.